Table 4.
Peak cytokine levels in the first month postinfusion in patients with and without count recovery at 1 month from CAR T-cell infusion
| Cytokine | Complete count recovery (n = 8)* | No complete count recovery (n = 33)* | Adjusted P† |
|---|---|---|---|
| IL-1 family | |||
| IL-1a | 86.5 (3.2-2 299.3) | 60.9 (3.2-627.8) | .96 |
| IL-1ra | 157.2 (3.2-1 446.5) | 149.7 (21.2-4 534.5) | .96 |
| IL-1b | 15.4 (1.4-1 864.9) | 3.4 (1.6-114.3) | .96 |
| Hematopoietin (class I cytokine) family | |||
| IL-2 | 17.7 (3.2-53.0) | 18.1 (0.9-188.1) | .96 |
| IL-3 | 4.4 (3.2-567.6) | 10.6 (1.9-206.0) | .96 |
| IL-4 | 22.9 (3.2-38.6) | 3.2 (2.7-148.0) | .96 |
| IL-5 | 6.4 (1.9-182.3) | 21.7 (1.0-257.1) | .96 |
| IL-6 | 72.3 (21.5-10 000.0) | 278.3 (3.2-13 538.0) | .96 |
| IL-7 | 21.6 (6.2-16 317.9) | 18.7 (3.2-323.0) | .96 |
| IL-9 | 3.9 (2.3-105.3) | 3.2 (1.1-53.1) | .96 |
| IL-12p40 | 82.5 (3.2-167.4) | 46.6 (3.2-256.0) | .96 |
| IL-12p70 | 12.2 (3.2- 38.2) | 7.0 (3.2-67.6) | .96 |
| IL-13 | 12.5 (3.2-51.1) | 12.5 (3.2-131.9) | .96 |
| IL-15 | 42.5 (18.6-280.3) | 100.5 (7.9-413.4) | .96 |
| IFN (class II cytokine) family | |||
| IFN-α3 | 71.3 (3.2-146.8) | 61.9 (2.8-343.3) | .96 |
| IFN-γ | 31.0 (3.2-817.7) | 69.6 (2.6-5 261.5) | .96 |
| IL-10 | 135.9 (9.7-4 676.5) | 337.2 (5.4-12 376.4) | .96 |
| Growth factors | |||
| GM-CSF | 89.6 (3.2-688.4) | 105.4 (1.8-1 541.5) | .96 |
| G-CSF | 1 287.5 (219.7-45 344.7) | 4 823.9 (51.3-125 780.0) | .96 |
| EGF | 609.6 (253.3-1 483.3) | 303.6 (67.3-1 459.5) | .96 |
| FGF-2 | 188.3 (79.8-681.0) | 120.3 (39.2-670.4) | .96 |
| TGF-α | 24.2 (3.2-52.3) | 8.7 (3.2-67.2) | .96 |
| VEGF | 1 182.4 (139.1-3 795.0) | 249.5 (3.2-3 123.0) | .18 |
| TNF family | |||
| TNF-α | 41.3 (3.2-358.2) | 54.5 (17.1-450.5) | .96 |
| TNF-β | 26.7 (8.2-291.0) | 12.3 (3.2-434.2) | .96 |
| sCD40L | 20 117.5 (149.9-1 702 924.4) | 13 716.2 (994.3-9 087 239.4) | .96 |
| IL-17 family | |||
| IL-17a | 9.4 (3.2-51.9) | 7.1 (3.0-105.0) | .96 |
| Chemokines | |||
| Eotaxin | 339.5 (215.7-505.9) | 298.5 (91.4-748.3) | .96 |
| MCP-1 | 1827.0 (364.5-4932100.3) | 6 496.7 (698.1-128 465.0) | .96 |
| MCP-3 | 117.0 (8.4-4816.5) | 63.3 (3.2-826.1) | .96 |
| MDC | 1636.0 (1202.2-5056.6) | 840.2 (153.8-4 339.7) | .06 |
| MIP-1a | 95.0 (24.1-10000.0) | 80.1 (13.1-430.6) | .96 |
| MIP-1b | 100.7 (72.6-9520.2) | 94.8 (28.4-499.6) | .96 |
| IP-10 | 1479.6 (61.2-33242.5) | 6 476.3 (553.7-70 391.5) | .96 |
| IL-8 | 907.3 (5.6-260142.8) | 1287.1 (43.6-40 534.0) | .96 |
| GRO | 1543.8 (478.3-14175.4) | 2482.8 (821.3-17 728.9) | .96 |
| Fractalkine | 307.9 (51.4-4 223.9) | 499.2 (7.2-70 519.7) | .96 |
| TK receptor ligand | |||
| FLT-3L | 515.4 (8.6-431.1) | 1223.9 (8.1-3 087.9) | .96 |
EGF, epidermal growth factor; FLT-3L, FMS-like tyrosine kinase 3 ligand; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; GRO, growth regulatory oncogene; IP-10, IFN-γ-inducible protein 10; MCP, monocyte chemoattractant protein; sCD40L, soluble CD40 ligand; TK, tyrosine kinase; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor.
*
Data are median (range) reported in pg/mL.
†
Wilcoxon rank-sum test P values were adjusted for 38 comparisons using the Benjamini-Hochberg method.